Rachel Klemovitch, Assistant Editor06.27.24
Paragonix Technologies has launched the PancreasPak Organ Preservation System, the first FDA-cleared device designed to protect and monitor donor pancreases during transportation. Pre-orders for this technology begin on June 27, 2024, with full availability planned for September 1, 2024.
“Our team is thrilled to introduce this advanced technology to the pancreatic transplant community,” said Dr. Lisa Anderson, CEO and President of Paragonix. “This milestone demonstrates our dedication to advancing the boundaries of organ transplantation excellence. We are honored to stand at the forefront of preservation and provide unparalleled support to countless patients in need of a heart, lung, liver, and now, pancreas. To be at the forefront and be the first company to provide pancreas preservation technology is a tremendous achievement and consistent with our commitment to service all transplant and donor patients.”
The PancreasPak System uses the same principles as the SherpaPak Cardiac Transport System to track and control pancreatic transplantation. The system offers a controlled environment with digital monitors, keeping the pancreas at an optimal thermal range of 4-8°C for up to 21 hours.
“This is an incredibly exciting time for pancreas transplantation. Preservation impacts organ function, and better preservation would allow us to help more patients. Until now, there has been a distinct lack of innovation within the pancreatic market specifically,” said Dr. Joseph Scalea, Vice Chair of Innovation, Department of Surgery, from Medical University of South Carolina. “An advanced preservation device has the potential to change everything. In just a few short months, we will finally have a tool tailored specifically to our needs, that aligns with our goal to substantially enhance organ viability and patient outcomes.”